Tell the Biden Administration: Stop Insurance Companies from Double-Dipping at Patients’ Expense

Countless Americans rely on copay assistance to afford the medications they need, especially those living with serious and chronic diseases like hemophilia, rheumatoid arthritis, HIV/AIDS, lupus, certain types of cancer, and others.

With copay assistance accumulator programs, or CAAPs, insurers collect patients’ cost-sharing assistance but do not reduce the patients’ deductibles.

In September a federal court struck down this practice that allows insurance companies to double dip at patients’ expense.

Please join us in encouraging the Biden administration to affirm the court’s ruling and provide cost-sharing assistance to patients who need it to afford life-saving treatment.